Cimetidine repurposed as a potential immunomodulatory agent against colorectal carcinoma: A systematic review

Abstract

Objective

To determine the survival benefit and immunomodulatory effects of cimetidine pre-, peri- or post-operatively in patients with colorectal cancer (CRC).

Methods

A systematic review was conducted using PubMed and Cochrane Library to retrieve randomized control trials (RCTs) that investigated the effects of cimetidine on survival and immunomodulation via improvement in tumor infiltrating lymphocytes (TILs) and peripheral blood lymphocytes. The review was carried out in accordance with the extended Preferred Reporting Items for Systematic Reviews and Meta-analyses.

Results

Four studies with the total of 267 patients were included in this systematic review. Treatment duration varied from 5 days to 1 year. Two studies reported a significant TIL response in the resected specimens after administering cimetidine, while one RCT showed an escalation of CD₃, CD₄ and CD₅₇ lymphocytes in peripheral blood compared to the baseline following cimetidine treatment (p < 0.01). Of the three trials that examined the effects of cimetidine on survival, only two studies revealed significant survival benefit while the remaining study only showed a trend towards survival benefit.

Conclusion

Repurposing of existing drugs like cimetidine has a potential to offer a survival benefit by acting as an immunomodulatory agent in patients undergoing curative resection for CRC. However, the heterogeneity seen in current studies and the evolvement of adjunctive therapies for CRC warrant large-scale, well-designed prospective RCTs to establish the efficacy of cimetidine in CRC.

Keywords

Cimetidine colorectal carcinoma survival repurpose

Get full access to this article

View all access options for this article.

References

Langedijk

, et al. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 2015; 20: 1027–1034.

Shim

Liu

. Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci 2014; 10: 654–663.

Parvathaneni

, et al. Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today 2019; 24: 2076–2085.

Mármol

, et al. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 2017; 18: 197.

Edrei

, et al. Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. Br J Cancer 2012; 107: 658–666.

Fan

, et al. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci 2021; 17: 3837–3849.

Espí

, et al. Relationship of curative surgery on natural killer cell activity in colorectal cancer. Dis Colon Rectum 1996; 39: 429–434.

Hansbrough

, et al. Altered helper and suppressor lymphocyte populations in surgical patients. A measure of postoperative immunosuppression. Am J Surg 1984; 148: 303–307.

Lin

, et al. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial. World J Gastroenterol 2004; 10: 136–142.

10.

Drugs@FDA. FDA Approved Drug Products Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017939.

11.

Pantziarka

, et al. Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. Ecancermedicalscience 2014; 8: 485.

12.

Kikuchi

, et al. Augmented natural killer activity in ovarian cancer patients treated with cimetidine. Eur J Cancer Clin Oncol 1986; 22: 1037–1043.

13.

Losurdo

, et al. Histamine and histaminergic receptors in colorectal cancer: from basic science to evidence-based medicine. Anticancer Agents Med Chem 2018; 18: 15–20.

14.

covidence. What is PRISMA guideline & what’s new in the 2020 guideline? ; Available from: https://www.covidence.org/blog/what-is-prisma-whats-new-in-the-2020-guideline-2/?campaignid=13462011761&adgroupid=122889437189&adid=526907496145&gclid=Cj0KCQjwrMKmBhCJARIsAHuEAPRtv1F95veroIBUbYsCUQosQ9rmJyXBtnSzBunQ5GBPs9a-zpE_UU0aAiqzEALw_wcB.

15.

Berger

Alperson

. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials 2009; 4: 79–88.

16.

Kelly

, et al. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumor-associated lymphocytes. Cancer 1999; 85: 1658–1663.

17.

Adams

Morris

. Pilot study--cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer 1997; 80: 15–21.

18.

Matsumoto

, et al. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 2002; 86: 161–167.

19.

Goel

Khanna

Kishore

. Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res 2010; 1: 274–278.

20.

Rocklin

Greineder

Melmon

. Histamine-induced suppressor factor (HSF): further studies on the nature of the stimulus and the cell which produces it. Cell Immunol 1979; 44: 404–415.

21.

Hamid

Ross

Ward

. The effect of cimetidine on immunological parameters in Crohn's disease: a double blind trial. Immunol Lett 1983; 6: 293–298.

22.

Adams

Lawson

Morris

. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut 1994; 35: 1632–1636.

23.

Lawson

Adams

Morris

. Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. Br J Cancer 1996; 73: 872–876.

24.

Harvey

, et al. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol 1984; 18: 421–430.

25.

Links

, et al. A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. Eur J Surg Oncol 1995; 21: 523–525.

26.

Hatlebakk

Berstad

. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386–406.